כל הפוסטים בעדכונים

Abstract To investigate the effectiveness, safety, and tolerability of vortioxetine in patients treated at therapeutic doses (5–20 mg/day) for both acute and maintenance treatment, patient-level

Abstract Objectives: To assess the relative efficacy and tolerability of vortioxetine against different antidepressant monotherapies in patients with major depressive disorder

Abstract Objective: Antidepressants are frequently associated with treatment-emergent sexual dysfunction (TESD). Vortioxetine, which was approved for patients with major depressive disorder

Abstract The safety and tolerability of vortioxetine in adults with major depressive disorder was assessed. Tolerability was based on the

Abstract Introduction: Sexual dysfunction is common with serotonergic antidepressants, including selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), and

Abstract Vortioxetine is approved for the treatment of adults with major depressive disorder. This open-label extension (OLE) study evaluated the

Abstract This multicenter, randomized, double-blind, placebo-controlled, active-referenced (duloxetine 60 mg), parallel-group study evaluated the short-term efficacy and safety of vortioxetine (10–20 mg)

Abstract Objective This randomised, double-blind, 12-week study compared efficacy and tolerability of flexible-dose treatment with vortioxetine (10–20 mg/day) versus agomelatine (25–50 mg/day)

Abstract This double-blind, randomized, placebo- and positive-controlled, parallel-group study evaluated the effect of vortioxetine (Lu AA21004), an investigational multimodal antidepressant,